Key result
Atenolol eliminates combined T wave and QRS alternans in pediatric LQT3 case.
Why the study?
To report a previously undescribed ECG pattern combining T wave alternans and QRS alternans in a patient with long QT syndrome.
Case Report (n=1)
No
Combined T wave and QRS alternans during sleep may represent a novel, high-risk ECG pattern in LQT3 patients that responds to beta-blocker therapy.
Answers are grounded in this paper and cite their sources.
May suggest beta-blocker suppression of combined alternans in pediatric LQT3; leaves open its risk stratification value pending larger studies.
We present a case of a new ECG phenomenon that has not been described previously in patients with long QT syndrome (LQTS). Prolongation of the QT interval (QTc) to 568 ms were revealed in girl 6 years old on the resting ECG. There were no symptoms, syncope or family history of sudden death. A molecular genetic study revealed mutation «de novo» in the SCN5A gene (p.Val1411Met), a pathogenic class V that typical for the third molecular genetic variant of LQTS (LQT3). During Holter monitoring a «hyperadaptation» of the QT interval was noted (slope QT/RR 0.37 with normal limit till 0,24). New ECG pattern of the combination T wave alternans and QRS alternans (AT/AQRS) at the night sleep (possibly in REM sleep) were recorded. This pattern has not been described previously in patients with LQTS. Atenolol 1 mg/kg was prescribed. During therapy, AT/AQRS did not record after 2 months. Possible mechanisms and prognostic significance of the identified ECG pattern, issues of treatment of patients with LQT3 are discussed. Conclusions: Combined of T wave alternans and QRS alternans (AT/AQRS) is a new ECG pattern in patients with LQTS that is likely to increase the risk of cardiac events. “Hyperadaptation” of the QT interval may be one of the electrocardiological features of LQT3. The emergence of the AT/AQRS pattern during REM sleep makes this period perhaps the most dangerous for the development of cardiac events in patients with LQT3.
No takes yet. Share an insight, caveat, or question.
Макаров et al. (2024) conducted a case report in Long QT syndrome type 3 (LQT3) (n=1). Atenolol was evaluated on Presence of combined T wave and QRS alternans (AT/AQRS) on Holter monitoring. Atenolol /kg/day eliminated the novel combined T wave and QRS alternans (AT/AQRS) ECG pattern after 2 months of therapy in a 6-year-old girl with long QT syndrome type 3.
Synapse has enriched 10 related papers. Consider them for comparative context: